Charles Schwab
IPSC icon

Charles Schwab’s Century Therapeutics IPSC Stock Holding History

Charles Schwab’s Portfolio IPSC Stock Details IPSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$928K Buy
378,867
+299,452
+377% +$684K ﹤0.01% 3029
2026
Q1 		$179K Buy
+79,415
New +$167K ﹤0.01% 3313
2025
Q3 		– Sell
-163,377
Closed -$91.3K – 3501
2025
Q2 		$91.3K Sell
163,377
-107,443
-40% -$57.6K ﹤0.01% 3419
2025
Q1 		$129K Sell
270,820
-86,985
-24% -$65.4K ﹤0.01% 3307
2024
Q4 		$361K Buy
357,805
+2,474
+0.7% +$3.37K ﹤0.01% 3233
2024
Q3 		$608K Sell
355,331
-43,049
-11% -$84.3K ﹤0.01% 3093
2024
Q2 		$1.02M Buy
398,380
+246,329
+162% +$779K ﹤0.01% 2931
2024
Q1 		$636K Buy
152,051
+3,290
+2% +$13.9K ﹤0.01% 2937
2023
Q4 		$494K Buy
148,761
+1,960
+1% +$3.57K ﹤0.01% 3077
2023
Q3 		$294K Sell
146,801
-13,257
-8% -$35.3K ﹤0.01% 3219
2023
Q2 		$506K Buy
160,058
+8,271
+5% +$26.7K ﹤0.01% 3049
2023
Q1 		$527K Sell
151,787
-1,536
-1% -$6.75K ﹤0.01% 2931
2022
Q4 		$787K Buy
153,323
+2,976
+2% +$28.1K ﹤0.01% 2861
2022
Q3 		$1.49M Buy
150,347
+55,616
+59% +$586K ﹤0.01% 2668
2022
Q2 		$796K Buy
94,731
+3,549
+4% +$34.8K ﹤0.01% 2882
2022
Q1 		$1.15M Buy
91,182
+13,681
+18% +$181K ﹤0.01% 2801
2021
Q4 		$1.23M Buy
77,501
+2,425
+3% +$45.6K ﹤0.01% 2832
2021
Q3 		$1.89M Buy
+75,076
New +$2.03M ﹤0.01% 2712

Other funds holding IPSC

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Charles Schwab's IPSC Position: Q2 2026 in Review

Charles Schwab increased its Century Therapeutics (IPSC) stake by 377% in Q2 2026, buying an estimated $684K and bringing the position to 378,867 shares worth $928K. The position accounts for ﹤0.01% of the portfolio, ranked #3029.

Charles Schwab first reported a position in IPSC in Q3 2021 and has held it in 18 quarters since. The position peaked at $1.89M in Q3 2021. 99 funds tracked by Wall St. Rank hold IPSC as of Q2 2026.

  • Charles Schwab held 378,867 shares of Century Therapeutics worth $928K as of Q2 2026.
  • Charles Schwab bought 299,452 Century Therapeutics shares in Q2 2026, an estimated $684K.
  • Century Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3029 holding.
  • Charles Schwab first reported a position in Century Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Charles Schwab's Century Therapeutics position peaked at $1.89M in Q3 2021.
  • 99 funds tracked by Wall St. Rank held Century Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.